RIBOPRO is not your average CDMO. Instead, we invest heavily in internal R&D with the believe that this is the best way to advance our knowledge, technologies, and product quality.
Our customers benefit from this investment by way of a better product and a higher chance of reaching the clinic/patient.
Activity & Quality
There are several challenges with the use of mRNA:
1. intracellular innate immunity resides in every cell-type, limits protein expression and can even induce cell-death. It is triggered by impurities (like dsRNA) and physicochemical properties of the mRNA itself.
2. A pure, mature mRNA containing a well-defined poly(A)tail and a cap on virtually all molecules is hard to obtain, as this is influenced by the sequence (structure)
3. (auto-catalytic) degradation of intact mRNA during production and storage for prolonged periods of time
1. Patented sequence-based de-immunization
We use our own RIBOSTEALTHTM technology to reduce (and it might even prevent) the induction of innate immunity against the mRNA. Click the button below to find out more about our RIBOSTEALTHTM technology. RIBOSTEALTHTM technology
2. In-house developed enzymes
RIBOPRO has developed RIBOPERFECTTM which contains our own variants of T7 RNAP. Click the button below to find out more about RIBOPERFECTTM. RIBOPERFECTTM technology
3. mRNA storage technologies.
It is well-known that mRNA is best stored at lower temperatures, especially at prolonged periods of time. We store and ship our mRNA products at -80°C (dry ice) to ensure maximum potency when arriving at your facility. Furthermore, we experiment with lyophilized and dried mRNA to enhance stability. In addition, our production process is swift and optimized for minimal in-process degradation. The use of high pure enzymes and the addition of RNAse-inhibitor prevents RNAse-mediated degradation.
Targeting & escape
The delivery of mRNA is a critical step in the overall performance of any mRNA. For in vivo and medicinal purposes, lipid nanoparticles remain the most advanced and often well-performing technology. Challenges remain:
1. Control over bio-distribution
2. Efficient endosomal escape
3. Suitable (lack of) immunogenicity
RIBOPRO has developed several technologies that address these issues:
1. Patented class of ionizable lipids
These lipids have an extra-ordinary low toxicity and immunogenicity, while having a reasonably high endosomal escape activity.
2. Proprietary core lipid system
By using a novel core lipid system, our LNPs show a substantially lower bio-distribution to the liver, allowing the (active) targeting towards other organs.